Altimmune
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Altimmune and other ETFs, options, and stocks.About ALT
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.
ALT Key Statistics
Stock Snapshot
Altimmune(ALT) stock is priced at $4.02, giving the company a market capitalization of 415.8M. It carries a P/E multiple of -3.72.
On 2025-12-24, Altimmune(ALT) stock traded between a low of $3.96 and a high of $4.11. Shares are currently priced at $4.02, which is +1.5% above the low and -2.2% below the high.
The Altimmune(ALT)'s current trading volume is 2.08M, compared to an average daily volume of 5.92M.
In the last year, Altimmune(ALT) shares hit a 52-week high of $8.05 and a 52-week low of $2.90.
In the last year, Altimmune(ALT) shares hit a 52-week high of $8.05 and a 52-week low of $2.90.
ALT News
New insider activity at Altimmune ( (ALT) ) has taken place on December 23, 2025. Claim 70% Off TipRanks This Holiday Season Unlock hedge-fund level data and po...
(RTTNews) - Altimmune, Inc. (ALT) shares fell 20.40%, closing at $4.02, down $1.03, after the company announced 48-week results from its Phase 2b IMPACT trial e...
Altimmune Inc. (NASDAQ:ALT) on Friday shared topline results from the IMPACT Phase 2b trial of pemvidutide. Patients had metabolic dysfunction-associated steat...
Analyst ratings
78%
of 9 ratingsMore ALT News
William Blair analyst Andy Hsieh has maintained their neutral stance on ALT stock, giving a Hold rating today. Claim 50% Off TipRanks Premium and Invest with Co...
Altimmune (ALT) announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patien...